Suppr超能文献

用于抗癌药物发现的小核核糖核蛋白多肽G与RBBP6的环指结构域之间分子相互作用的微量热泳分析

Microscale thermophoresis analysis of the molecular interaction between small nuclear ribonucleoprotein polypeptide G and the RING finger domain of RBBP6 towards anti-cancer drug discovery.

作者信息

Mabonga Lloyd, Masamba Priscilla, Basson Albertus Kotze, Kappo Abidemi Paul

机构信息

Department of Biochemistry and Microbiology, University of Zululand KwaDlangezwa 3886, South Africa.

Molecular Biophysics and Structural Biology (MBSB) Group, Department of Biochemistry, Faculty of Science, University of Johannesburg, Kingsway Campus Auckland Park 2006, South Africa.

出版信息

Am J Transl Res. 2021 Nov 15;13(11):12775-12785. eCollection 2021.

Abstract

Regulatory core-splicing proteins are now becoming highly promising therapeutic targets for the development of anti-cancer drugs. SNRPG and RBBP6 are two good examples of regulatory core-splicing proteins involved in tumorigenesis and tumor development whose multi-functional role is primarily mediated by protein-protein interactions. Over the years, skepticism abutting from the two onco-proteins has been mounting. Suggestive evidence using yeast 2-hybrid technique observed possible involvement between SNRPG and the RING finger domain of RBBP6. However, the putative interaction remains elusive and yet to be characterized. In this study, we developed the first MST-based assay to confirm the interaction between SNRPG and the RING finger domain of RBBP6. The results demonstrated a strong binding affinity between SNRPG and the RING finger domain of RBBP6 with a K in the low nanomolar concentration range of 3.1596 nM. The results are congruent with previous findings suggesting possible involvement between the two proteins in cancer-cell networks, thereby providing a new mechanistic insight into the interaction between SNRPG and the RING finger domain of RBBP6. The interaction is therapeutically relevant and represents a great milestone in the anti-cancer drug discovery space. Identification of small molecule inhibitors to modulate the binding affinity between the two proteins would therefore be a major breakthrough in the development of new PPI-focused anti-cancer drugs.

摘要

调控核心剪接蛋白正成为抗癌药物开发中极具前景的治疗靶点。SNRPG和RBBP6是参与肿瘤发生和肿瘤发展的调控核心剪接蛋白的两个良好例子,其多功能作用主要由蛋白质-蛋白质相互作用介导。多年来,人们对这两种癌蛋白的怀疑一直在增加。使用酵母双杂交技术的暗示性证据表明SNRPG与RBBP6的环指结构域之间可能存在关联。然而,这种假定的相互作用仍然难以捉摸,尚未得到表征。在本研究中,我们开发了首个基于 MST 的分析方法来证实SNRPG与RBBP6的环指结构域之间的相互作用。结果表明,SNRPG与RBBP6的环指结构域之间具有很强的结合亲和力,K值在3.1596 nM的低纳摩尔浓度范围内。这些结果与之前的研究结果一致,表明这两种蛋白质可能参与癌细胞网络,从而为SNRPG与RBBP6的环指结构域之间的相互作用提供了新的机制见解。这种相互作用具有治疗相关性,是抗癌药物发现领域的一个重大里程碑。因此,鉴定能够调节这两种蛋白质之间结合亲和力的小分子抑制剂将是新型PPI靶向抗癌药物开发的一项重大突破。

相似文献

5
Expression Analysis of RbBP6 in human cancers: a Prospective biomarker.
Anticancer Drugs. 2019 Sep;30(8):767-773. doi: 10.1097/CAD.0000000000000809.
7
Solution structure of RING finger-like domain of retinoblastoma-binding protein-6 (RBBP6) suggests it functions as a U-box.
J Biol Chem. 2012 Mar 2;287(10):7146-58. doi: 10.1074/jbc.M110.217059. Epub 2011 Nov 29.
9
Expression and function of retinoblastoma binding protein 6 (RBBP6) in human lung cancer.
Immunobiology. 2011 Oct;216(10):1065-73. doi: 10.1016/j.imbio.2011.05.004. Epub 2011 May 17.

本文引用的文献

3
MUC4-ErbB2 Oncogenic Complex: Binding studies using Microscale Thermophoresis.
Sci Rep. 2019 Nov 13;9(1):16678. doi: 10.1038/s41598-019-53099-0.
4
A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity.
Cancer Immunol Res. 2019 Nov;7(11):1864-1875. doi: 10.1158/2326-6066.CIR-18-0805. Epub 2019 Aug 28.
5
CA-170 - A Potent Small-Molecule PD-L1 Inhibitor or Not?
Molecules. 2019 Aug 1;24(15):2804. doi: 10.3390/molecules24152804.
6
Molecular Analysis of Protein-Protein Interactions in the Ethylene Pathway in the Different Ethylene Receptor Subfamilies.
Front Plant Sci. 2019 Jun 7;10:726. doi: 10.3389/fpls.2019.00726. eCollection 2019.
7
Venetoclax in the treatment of chronic lymphocytic leukemia.
Expert Opin Drug Metab Toxicol. 2019 May;15(5):353-366. doi: 10.1080/17425255.2019.1606211. Epub 2019 Apr 25.
8
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.
10
Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.
Sci Transl Med. 2018 Apr 11;10(436). doi: 10.1126/scitranslmed.aao3003.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验